Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jose-Alain Sahel, MD. Ph.D
Hopital Nationale des Quinze-Vingt, Paris France
Principal Investigator - Paul Yang, MD
Oregon Health & Science University, Portland, Oregon
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Investigational Site Number 250001
Paris, France
- Investigational Site Number 840002
Miami, Florida, United States
- Investigational Site Number 840005
Iowa City, Iowa, United States
- Investigational Site Number 840001
Portland, Oregon, United States
- Investigational Site Number 840004
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jun 2011
- Primary completion
- 16 Aug 2019
- Completion
- 16 Aug 2019
- Last update posted
- 14 Apr 2022
- Registered enrollment
- 27
- Registry id
- NCT01367444
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.